NTS071 for Cancer
(NTS071 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called NTS071 for certain types of cancer. The goal is to determine if this treatment is safe and effective for individuals with specific solid tumors that have a TP53 Y220C mutation. It is a single-arm study, meaning all participants receive the experimental treatment. Suitable candidates have advanced solid tumors, have undergone previous treatments, and still experience disease progression. Participants should have measurable tumors and be in good overall health without major other health issues. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that NTS071 is likely to be safe for humans?
Research has shown that NTS071 was safe in early studies. Tests with rats and dogs demonstrated that NTS071 was well-tolerated even at doses higher than those intended for humans. These results are promising for its safety in people. The treatment also passed initial safety checks by the FDA, allowing trials to continue. Although more information from human trials is needed, these early findings suggest NTS071 could be a safe option for people with certain types of cancer.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about NTS071 for cancer because it offers a novel approach compared to traditional treatments like chemotherapy and radiation. While most cancer treatments work by targeting rapidly dividing cells, NTS071 is believed to work through a unique mechanism that specifically targets cancer cells without affecting healthy ones, potentially reducing side effects. Additionally, NTS071 might be administered in a way that enhances its absorption and effectiveness, providing a more efficient treatment option. These features make NTS071 a promising candidate in the ongoing fight against cancer.
What evidence suggests that NTS071 might be an effective treatment for cancer?
Research has shown that NTS071 could be a promising treatment for solid tumors with the TP53 Y220C mutation. Early studies found NTS071 to be 20 times more effective than a similar drug, PC14586, when administered in the same amounts. It also performed better or required lower doses compared to other treatments. These results suggest that NTS071 could be a strong option for treating tumors with this mutation. The drug's success in these studies indicates potential effectiveness on various tumor types with the same mutation.12467
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors that have a specific genetic change called TP53 Y220C mutation. The detailed eligibility criteria are not provided, but typically include factors like the type and stage of cancer, previous treatments, overall health status, and other medical conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1: Dose Escalation
Participants undergo dose escalation to determine the maximum tolerated dose and observe dose-limiting toxicities
Phase 2a: Cohort Expansion
Participants receive treatment to evaluate safety, tolerability, and preliminary efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- NTS071
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nutshell Therapeutics (Shanghai) Co., LTD.
Lead Sponsor